Absci vs Insitro
Side-by-side comparison of AI visibility scores, market position, and capabilities
Absci is an AI drug creation company that combines generative AI with a synthetic biology platform to design novel therapeutic proteins from the ground up.
About
Absci is a publicly traded AI drug creation company founded in 2011 that went public in 2021 and has repositioned around generative AI for drug design. The company operates an integrated platform that uses generative AI to design novel antibodies and proteins, then validates them using high-throughput expression and biological assay systems in its own wet lab infrastructure. Absci's approach treats drug discovery as a generative design problem, using AI to propose protein sequences with desired therapeutic properties and then rapidly testing millions of candidates to identify viable drug leads. The company has established drug creation partnerships with major pharmaceutical companies including AstraZeneca, Merck, and EQT Life Sciences. Absci's technical differentiation lies in its ability to close the loop between AI-generated protein designs and experimental validation at unprecedented scale. The company represents a new category of AI-native biopharmaceutical company that combines computational and wet-lab capabilities to create drugs not discoverable through traditional means.
Drug discovery company founded by Daphne Koller integrating ML with high-throughput biology; raised $400M+ to build proprietary biological datasets for predicting drug targets and clinical outcomes in neurology, metabolic, and oncology programs.
About
Insitro is a drug discovery company founded in 2018 by Daphne Koller, a pioneer in machine learning and computational biology, having raised over $400M to build an integrated ML and biology platform. The company generates large-scale biological datasets using automated laboratory systems and human induced pluripotent stem cell models of disease, then trains machine learning models on this data to predict drug targets, patient stratification, and clinical outcomes. Unlike companies that apply ML to existing datasets, Insitro builds proprietary biological datasets specifically designed to train predictive models for drug discovery. The platform is being applied to neurological diseases, metabolic disorders, and oncology with the goal of identifying drug candidates more likely to succeed in clinical trials. Insitro has established partnerships with major pharmaceutical companies including Gilead Sciences and Bristol Myers Squibb to co-develop drugs using the platform. The company represents a model for how ML can be deeply integrated into pharmaceutical R&D rather than applied as a surface-level analytical layer.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.